These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26004134)

  • 1. Targeting of cancer stem cells by inhibitors of DNA and histone methylation.
    Momparler RL; Côté S
    Expert Opin Investig Drugs; 2015; 24(8):1031-43. PubMed ID: 26004134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting histone methyltransferase EZH2 as cancer treatment.
    Kondo Y
    J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of DNA and Histone Methylation by 5-Aza-2'-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells.
    Momparler RL; Côté S; Momparler LF; Idaghdour Y
    Front Oncol; 2017; 7():19. PubMed ID: 28261562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation.
    Momparler RL; Idaghdour Y; Marquez VE; Momparler LF
    Leuk Res; 2012 Aug; 36(8):1049-54. PubMed ID: 22472464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation.
    Momparler RL; Côté S; Momparler LF; Idaghdour Y
    Clin Epigenetics; 2014; 6(1):19. PubMed ID: 25313314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 as a potential target in cancer therapy.
    McCabe MT; Creasy CL
    Epigenomics; 2014 Jun; 6(3):341-51. PubMed ID: 25111487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
    Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
    Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
    Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
    Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
    Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
    Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
    Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
    Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrations of EZH2 in cancer.
    Chase A; Cross NC
    Clin Cancer Res; 2011 May; 17(9):2613-8. PubMed ID: 21367748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.
    Miranda TB; Cortez CC; Yoo CB; Liang G; Abe M; Kelly TK; Marquez VE; Jones PA
    Mol Cancer Ther; 2009 Jun; 8(6):1579-88. PubMed ID: 19509260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression.
    Ning X; Shi Z; Liu X; Zhang A; Han L; Jiang K; Kang C; Zhang Q
    Cancer Lett; 2015 Apr; 359(2):198-205. PubMed ID: 25595591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2 in Bladder Cancer, a Promising Therapeutic Target.
    Martínez-Fernández M; Rubio C; Segovia C; López-Calderón FF; Dueñas M; Paramio JM
    Int J Mol Sci; 2015 Nov; 16(11):27107-32. PubMed ID: 26580594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polycomb genes and cancer: time for clinical application?
    Crea F; Paolicchi E; Marquez VE; Danesi R
    Crit Rev Oncol Hematol; 2012 Aug; 83(2):184-93. PubMed ID: 22112692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of the EZH2 histone methyltransferase in cancer epigenetics.
    Simon JA; Lange CA
    Mutat Res; 2008 Dec; 647(1-2):21-9. PubMed ID: 18723033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
    Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
    J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
    Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
    Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
    Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC
    Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
    Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
    Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.